export const defaultResearchPapers = [
  { id: "1", title: "Novel CAR-T Cell Engineering Approaches for Solid Tumor Treatment", authors: "Zhang et al.", journal: "Nature Medicine", date: "Dec 2024", citations: 47, abstract: "This study presents breakthrough modifications to CAR-T cell constructs that enhance tumor infiltration and persistence in solid tumor microenvironments...", keywords: ["CAR-T", "Immunotherapy", "Solid Tumors", "Cell Engineering"], trending: true, link: "https://www.nature.com/nm/" },
  { id: "2", title: "mRNA Lipid Nanoparticle Optimization for Enhanced Tissue Targeting", authors: "Chen & Williams", journal: "Science Translational Medicine", date: "Dec 2024", citations: 32, abstract: "A comprehensive analysis of ionizable lipid structures and their impact on mRNA delivery efficiency to specific tissue types...", keywords: ["mRNA", "Lipid Nanoparticles", "Drug Delivery", "Gene Therapy"], trending: true, link: "https://www.science.org/journal/stm" },
  { id: "3", title: "CRISPR-Based Approaches to Rare Genetic Disease Treatment", authors: "Patel et al.", journal: "Cell", date: "Nov 2024", citations: 89, abstract: "Review of current clinical applications of CRISPR gene editing for rare diseases, including outcomes from ongoing trials...", keywords: ["CRISPR", "Gene Editing", "Rare Diseases", "Clinical Trials"], trending: false, link: "https://www.cell.com/cell/home" },
  { id: "4", title: "AI-Driven Drug Discovery: From Target Identification to Lead Optimization", authors: "Kumar & Anderson", journal: "Nature Reviews Drug Discovery", date: "Nov 2024", citations: 156, abstract: "Comprehensive overview of machine learning applications across the drug discovery pipeline, with focus on recent successes...", keywords: ["AI", "Drug Discovery", "Machine Learning", "Lead Optimization"], trending: true, link: "https://www.nature.com/nrd/" },
  { id: "5", title: "Antibody-Drug Conjugate Design Principles for Improved Therapeutic Index", authors: "Thompson et al.", journal: "Journal of Medicinal Chemistry", date: "Oct 2024", citations: 28, abstract: "Structure-activity relationship analysis of linker chemistry and payload selection in next-generation ADCs...", keywords: ["ADC", "Antibody", "Linker Chemistry", "Oncology"], trending: false, link: "https://pubs.acs.org/journal/jmcmar" },
  { id: "6", title: "GLP-1 Receptor Agonists: Beyond Diabetes to Cardiovascular Protection", authors: "Martinez et al.", journal: "The Lancet", date: "Dec 2024", citations: 234, abstract: "Meta-analysis of cardiovascular outcomes in patients treated with GLP-1 receptor agonists across multiple indications...", keywords: ["GLP-1", "Cardiovascular", "Diabetes", "Obesity"], trending: true, link: "https://www.thelancet.com" },
  { id: "7", title: "Bispecific Antibodies in Hematologic Malignancies: A New Era", authors: "Liu & Santos", journal: "Blood", date: "Dec 2024", citations: 67, abstract: "Comprehensive review of approved and investigational bispecific antibodies for treatment of leukemia and lymphoma...", keywords: ["Bispecific Antibodies", "Leukemia", "Lymphoma", "Immunotherapy"], trending: true, link: "https://ashpublications.org/blood" },
  { id: "8", title: "Proteolysis Targeting Chimeras (PROTACs): Clinical Translation Progress", authors: "Wang et al.", journal: "Nature Reviews Drug Discovery", date: "Nov 2024", citations: 112, abstract: "Update on PROTAC technology advancement from preclinical studies to first-in-human clinical trials...", keywords: ["PROTAC", "Protein Degradation", "Drug Discovery", "Targeted Therapy"], trending: true, link: "https://www.nature.com/nrd/" },
  { id: "9", title: "Next-Generation Sequencing in Liquid Biopsy: Minimal Residual Disease Detection", authors: "Johnson et al.", journal: "Journal of Clinical Oncology", date: "Nov 2024", citations: 89, abstract: "Validation study of ctDNA-based MRD detection for treatment response monitoring in solid tumors...", keywords: ["Liquid Biopsy", "ctDNA", "MRD", "Oncology"], trending: false, link: "https://ascopubs.org/journal/jco" },
  { id: "10", title: "Microbiome-Based Therapeutics: From Research to Clinic", authors: "Garcia et al.", journal: "Science", date: "Oct 2024", citations: 145, abstract: "Review of microbiome modulation strategies and their therapeutic applications in inflammatory diseases...", keywords: ["Microbiome", "Gut-Brain Axis", "Inflammatory Disease", "Probiotics"], trending: true, link: "https://www.science.org" },
  { id: "11", title: "Advances in Oligonucleotide Therapeutics: siRNA and ASO Platforms", authors: "Smith & Nakamura", journal: "Nature Biotechnology", date: "Oct 2024", citations: 78, abstract: "Comparative analysis of delivery strategies and chemical modifications for nucleic acid therapeutics...", keywords: ["siRNA", "ASO", "Oligonucleotide", "Gene Silencing"], trending: false, link: "https://www.nature.com/nbt/" },
  { id: "12", title: "Checkpoint Inhibitor Combinations: Optimizing Immunotherapy Regimens", authors: "Brown et al.", journal: "NEJM", date: "Dec 2024", citations: 312, abstract: "Randomized trial comparing dual checkpoint blockade versus sequential therapy in advanced melanoma...", keywords: ["Checkpoint Inhibitors", "PD-1", "CTLA-4", "Melanoma"], trending: true, link: "https://www.nejm.org" },
  { id: "13", title: "AAV Gene Therapy: Overcoming Immunogenicity Challenges", authors: "Taylor et al.", journal: "Molecular Therapy", date: "Nov 2024", citations: 56, abstract: "Strategies to mitigate anti-AAV immune responses and enable redosing in gene therapy applications...", keywords: ["AAV", "Gene Therapy", "Immunogenicity", "Vector Engineering"], trending: false, link: "https://www.cell.com/molecular-therapy" },
  { id: "14", title: "Radiopharmaceutical Theranostics in Prostate Cancer", authors: "Miller et al.", journal: "Journal of Nuclear Medicine", date: "Oct 2024", citations: 43, abstract: "Clinical outcomes with PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer...", keywords: ["Radiopharmaceutical", "PSMA", "Prostate Cancer", "Theranostics"], trending: true, link: "https://jnm.snmjournals.org" },
  { id: "15", title: "Digital Therapeutics for Mental Health: Evidence and Implementation", authors: "Davis & Kim", journal: "The Lancet Psychiatry", date: "Nov 2024", citations: 87, abstract: "Systematic review of FDA-cleared digital therapeutics for depression, anxiety, and substance use disorders...", keywords: ["Digital Therapeutics", "Mental Health", "mHealth", "Psychiatry"], trending: false, link: "https://www.thelancet.com/psychiatry" },
  { id: "16", title: "Cell-Free DNA Methylation Patterns for Early Cancer Detection", authors: "Wilson et al.", journal: "Cancer Discovery", date: "Dec 2024", citations: 98, abstract: "Multi-cancer early detection test validation using methylation-based liquid biopsy approach...", keywords: ["cfDNA", "Methylation", "Cancer Screening", "Early Detection"], trending: true, link: "https://aacrjournals.org/cancerdiscovery" },
  { id: "17", title: "Allosteric Modulators: Expanding the Druggable Proteome", authors: "Lee et al.", journal: "Cell Chemical Biology", date: "Oct 2024", citations: 34, abstract: "Discovery and optimization of allosteric small molecules targeting traditionally undruggable proteins...", keywords: ["Allosteric", "Small Molecules", "Drug Design", "Medicinal Chemistry"], trending: false, link: "https://www.cell.com/cell-chemical-biology" },
  { id: "18", title: "Synthetic Biology Approaches to Living Medicines", authors: "Robinson et al.", journal: "Nature Medicine", date: "Nov 2024", citations: 67, abstract: "Engineering bacteria and human cells as programmable therapeutic agents for cancer and autoimmune diseases...", keywords: ["Synthetic Biology", "Living Medicines", "Cell Therapy", "Immunology"], trending: true, link: "https://www.nature.com/nm/" },
  { id: "19", title: "Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity", authors: "Anderson et al.", journal: "Cell", date: "Dec 2024", citations: 123, abstract: "High-resolution spatial mapping of immune infiltrates and therapeutic response prediction...", keywords: ["Spatial Transcriptomics", "TME", "Immunotherapy", "Biomarkers"], trending: true, link: "https://www.cell.com/cell/home" },
  { id: "20", title: "Base Editing: Precision Genome Engineering Without Double-Strand Breaks", authors: "Huang et al.", journal: "Nature Biotechnology", date: "Oct 2024", citations: 89, abstract: "Clinical development of cytosine and adenine base editors for monogenic disease correction...", keywords: ["Base Editing", "CRISPR", "Genome Engineering", "Rare Diseases"], trending: false, link: "https://www.nature.com/nbt/" },
  { id: "21", title: "Targeting Protein-Protein Interactions with Macrocyclic Peptides", authors: "Yamamoto et al.", journal: "Journal of Medicinal Chemistry", date: "Nov 2024", citations: 45, abstract: "Design strategies for cell-permeable macrocycles disrupting oncogenic protein complexes...", keywords: ["Macrocycles", "PPI", "Peptide Drug", "Cancer"], trending: false, link: "https://pubs.acs.org/journal/jmcmar" },
  { id: "22", title: "Tumor-Infiltrating Lymphocyte Therapy: Manufacturing Advances", authors: "Peters et al.", journal: "Blood Advances", date: "Dec 2024", citations: 56, abstract: "Automation and closed-system approaches to scale TIL production for solid tumor treatment...", keywords: ["TIL", "Cell Manufacturing", "Solid Tumors", "Immunotherapy"], trending: true, link: "https://ashpublications.org/bloodadvances" },
  { id: "23", title: "Exosome-Based Drug Delivery: From Bench to Bedside", authors: "Fernandez et al.", journal: "Advanced Drug Delivery Reviews", date: "Oct 2024", citations: 78, abstract: "Engineering extracellular vesicles for targeted delivery of small molecules and nucleic acids...", keywords: ["Exosomes", "Drug Delivery", "Extracellular Vesicles", "Nanomedicine"], trending: false, link: "https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews" },
  { id: "24", title: "Covalent Inhibitors: Renaissance in Drug Discovery", authors: "Clark et al.", journal: "Nature Reviews Drug Discovery", date: "Nov 2024", citations: 134, abstract: "Rational design of targeted covalent inhibitors with improved selectivity and safety profiles...", keywords: ["Covalent Inhibitors", "KRAS", "EGFR", "Drug Design"], trending: true, link: "https://www.nature.com/nrd/" },
  { id: "25", title: "iPSC-Derived Cell Therapies for Neurological Disorders", authors: "Nakagawa et al.", journal: "Cell Stem Cell", date: "Dec 2024", citations: 67, abstract: "Clinical translation of induced pluripotent stem cell-derived neurons and glia for Parkinson's disease...", keywords: ["iPSC", "Parkinson's", "Cell Therapy", "Regenerative Medicine"], trending: true, link: "https://www.cell.com/cell-stem-cell" },
  { id: "26", title: "Molecular Glue Degraders: A New Frontier in Targeted Therapy", authors: "Morgan et al.", journal: "Science", date: "Nov 2024", citations: 89, abstract: "Discovery and mechanistic understanding of molecular glue-induced neo-substrate degradation...", keywords: ["Molecular Glue", "Protein Degradation", "E3 Ligase", "Cancer"], trending: true, link: "https://www.science.org" },
  { id: "27", title: "Real-World Evidence in Oncology Drug Development", authors: "Sullivan et al.", journal: "Journal of Clinical Oncology", date: "Oct 2024", citations: 56, abstract: "Regulatory perspectives on incorporating RWE into cancer drug approval and label expansion...", keywords: ["RWE", "Regulatory Science", "Oncology", "FDA"], trending: false, link: "https://ascopubs.org/journal/jco" },
  { id: "28", title: "Antibody Engineering for Enhanced Effector Functions", authors: "Richardson et al.", journal: "mAbs", date: "Nov 2024", citations: 45, abstract: "Fc engineering strategies to optimize ADCC, ADCP, and CDC activity in therapeutic antibodies...", keywords: ["Antibody Engineering", "Fc Optimization", "ADCC", "Immunotherapy"], trending: false, link: "https://www.tandfonline.com/toc/kmab20/current" },
  { id: "29", title: "Neurodegenerative Disease: Targeting Protein Aggregation", authors: "Bennett et al.", journal: "Nature Neuroscience", date: "Dec 2024", citations: 112, abstract: "Small molecule and immunotherapy approaches to clear pathological protein aggregates in Alzheimer's and Parkinson's...", keywords: ["Neurodegeneration", "Amyloid", "Tau", "Alpha-Synuclein"], trending: true, link: "https://www.nature.com/neuro/" },
  { id: "30", title: "Adoptive NK Cell Therapy: Expanding the Immunotherapy Landscape", authors: "Kim et al.", journal: "Blood", date: "Oct 2024", citations: 78, abstract: "Engineering strategies to enhance NK cell persistence and cytotoxicity in hematologic malignancies...", keywords: ["NK Cells", "Immunotherapy", "Cell Therapy", "Leukemia"], trending: false, link: "https://ashpublications.org/blood" },
  { id: "31", title: "Tissue-Resident Memory T Cells in Anti-Tumor Immunity", authors: "Murray et al.", journal: "Immunity", date: "Nov 2024", citations: 67, abstract: "Understanding TRM cell biology to enhance vaccine and checkpoint inhibitor responses...", keywords: ["TRM Cells", "Immunology", "Cancer Vaccines", "Checkpoint Therapy"], trending: true, link: "https://www.cell.com/immunity" },
  { id: "32", title: "Alpha-Emitting Radionuclides for Targeted Cancer Therapy", authors: "Lewis et al.", journal: "Clinical Cancer Research", date: "Dec 2024", citations: 34, abstract: "Clinical development of actinium-225 and thorium-227 labeled antibodies for micrometastatic disease...", keywords: ["Alpha Therapy", "Radionuclide", "Targeted Therapy", "Oncology"], trending: false, link: "https://aacrjournals.org/clincancerres" },
  { id: "33", title: "Oncolytic Virus Therapy: Mechanisms and Combinations", authors: "Barker et al.", journal: "Cancer Cell", date: "Oct 2024", citations: 89, abstract: "Armed oncolytic viruses combining direct lysis with immune activation for solid tumor treatment...", keywords: ["Oncolytic Virus", "Immunotherapy", "Cancer", "Gene Therapy"], trending: true, link: "https://www.cell.com/cancer-cell" },
  { id: "34", title: "TIGIT Pathway Inhibition: Next-Generation Checkpoint Therapy", authors: "Foster et al.", journal: "Nature Medicine", date: "Nov 2024", citations: 123, abstract: "Phase II results of anti-TIGIT antibodies in combination with PD-1 blockade...", keywords: ["TIGIT", "Checkpoint Inhibitor", "Immunotherapy", "Oncology"], trending: true, link: "https://www.nature.com/nm/" },
  { id: "35", title: "Organ-on-Chip Technology for Drug Safety Assessment", authors: "Ingber et al.", journal: "Nature Reviews Drug Discovery", date: "Dec 2024", citations: 78, abstract: "Microphysiological systems replacing animal models in toxicity testing and efficacy prediction...", keywords: ["Organ-on-Chip", "Drug Safety", "In Vitro Models", "Microfluidics"], trending: false, link: "https://www.nature.com/nrd/" },
  { id: "36", title: "Long-Acting Injectable Formulations: Improving Patient Adherence", authors: "Harper et al.", journal: "Journal of Controlled Release", date: "Oct 2024", citations: 45, abstract: "Depot technologies enabling monthly to yearly dosing for chronic disease management...", keywords: ["Long-Acting", "Injectable", "Drug Delivery", "Formulation"], trending: false, link: "https://www.sciencedirect.com/journal/journal-of-controlled-release" },
  { id: "37", title: "Prime Editing: Versatile Genome Modification Without DNA Templates", authors: "Liu et al.", journal: "Cell", date: "Nov 2024", citations: 234, abstract: "Advances in prime editing efficiency and delivery enabling therapeutic applications...", keywords: ["Prime Editing", "CRISPR", "Genome Editing", "Gene Therapy"], trending: true, link: "https://www.cell.com/cell/home" },
  { id: "38", title: "Antibody-siRNA Conjugates: Precision Gene Silencing", authors: "Crooke et al.", journal: "Molecular Therapy - Nucleic Acids", date: "Dec 2024", citations: 56, abstract: "Antibody-mediated delivery of siRNA for extrahepatic tissue targeting...", keywords: ["siRNA", "Antibody Conjugate", "Gene Silencing", "Drug Delivery"], trending: true, link: "https://www.cell.com/molecular-therapy-family/nucleic-acids" },
  { id: "39", title: "Cancer Neoantigen Vaccines: Personalized Immunotherapy", authors: "Sahin et al.", journal: "Nature", date: "Oct 2024", citations: 189, abstract: "Clinical outcomes with mRNA-based personalized neoantigen vaccines in combination with checkpoint inhibitors...", keywords: ["Neoantigen", "Cancer Vaccine", "mRNA", "Personalized Medicine"], trending: true, link: "https://www.nature.com" },
  { id: "40", title: "Circular RNA Therapeutics: A New Modality Emerges", authors: "Wesselhoeft et al.", journal: "Nature Biotechnology", date: "Nov 2024", citations: 67, abstract: "Engineering circular RNAs for enhanced stability and translation in therapeutic applications...", keywords: ["circRNA", "RNA Therapeutics", "Gene Expression", "Drug Development"], trending: false, link: "https://www.nature.com/nbt/" },
];

// Default clinical trials data
export const defaultTrials = [
  {
    id: "NCT05580562",
    title: "A Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Carcinoma",
    sponsor: "Merck Sharp & Dohme LLC",
    phase: "Phase III",
    status: "Active",
    indication: "Endometrial Carcinoma",
    primaryEndpoint: "Progression-Free Survival (PFS)",
    secondaryEndpoints: ["Overall Survival", "Objective Response Rate", "Duration of Response"],
    enrollment: 875,
    startDate: "October 2022",
    completionDate: "December 2026"
  },
  {
    id: "NCT04379596",
    title: "Trastuzumab Deruxtecan in HER2-Low Breast Cancer (DESTINY-Breast04)",
    sponsor: "Daiichi Sankyo",
    phase: "Phase III",
    status: "Completed",
    indication: "HER2-Low Breast Cancer",
    primaryEndpoint: "Progression-Free Survival in HR+ Cohort",
    secondaryEndpoints: ["Overall Survival", "ORR", "Safety Profile"],
    enrollment: 557,
    startDate: "January 2020",
    completionDate: "June 2024"
  },
  {
    id: "NCT04819178",
    title: "Sacituzumab Govitecan vs Treatment of Physician's Choice in HR+/HER2- Breast Cancer",
    sponsor: "Gilead Sciences",
    phase: "Phase III",
    status: "Recruiting",
    indication: "HR+/HER2- Metastatic Breast Cancer",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "Clinical Benefit Rate", "Quality of Life"],
    enrollment: 650,
    startDate: "March 2021",
    completionDate: "September 2025"
  },
  {
    id: "NCT05629585",
    title: "Oral SERD Elacestrant in ER+/HER2- Advanced Breast Cancer (EMERALD)",
    sponsor: "Stemline Therapeutics",
    phase: "Phase III",
    status: "Active",
    indication: "ER+/HER2- Advanced Breast Cancer",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "ORR", "Time to Response"],
    enrollment: 478,
    startDate: "November 2022",
    completionDate: "March 2026"
  },
  {
    id: "NCT04072952",
    title: "Sotorasib in KRAS G12C Mutated Non-Small Cell Lung Cancer (CodeBreaK 200)",
    sponsor: "Amgen",
    phase: "Phase III",
    status: "Completed",
    indication: "KRAS G12C-Mutated NSCLC",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "Objective Response Rate", "Disease Control Rate"],
    enrollment: 345,
    startDate: "August 2020",
    completionDate: "February 2024"
  },
  {
    id: "NCT04538378",
    title: "Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma (HIMALAYA)",
    sponsor: "AstraZeneca",
    phase: "Phase III",
    status: "Active",
    indication: "Unresectable Hepatocellular Carcinoma",
    primaryEndpoint: "Overall Survival",
    secondaryEndpoints: ["PFS", "ORR", "Duration of Response", "Time to Progression"],
    enrollment: 1171,
    startDate: "September 2020",
    completionDate: "August 2025"
  },
  {
    id: "NCT05194995",
    title: "Atezolizumab Plus Cabozantinib in Advanced Renal Cell Carcinoma",
    sponsor: "Roche",
    phase: "Phase III",
    status: "Recruiting",
    indication: "Advanced Renal Cell Carcinoma",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "ORR", "Safety"],
    enrollment: 520,
    startDate: "January 2022",
    completionDate: "June 2026"
  },
  {
    id: "NCT04887870",
    title: "Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma (SPOTLIGHT)",
    sponsor: "Astellas Pharma",
    phase: "Phase III",
    status: "Active",
    indication: "Gastric/GEJ Adenocarcinoma",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "ORR", "Quality of Life"],
    enrollment: 565,
    startDate: "May 2021",
    completionDate: "December 2025"
  },
  {
    id: "NCT04821622",
    title: "Tislelizumab in First-Line Esophageal Squamous Cell Carcinoma (RATIONALE 306)",
    sponsor: "BeiGene",
    phase: "Phase III",
    status: "Active",
    indication: "Esophageal Squamous Cell Carcinoma",
    primaryEndpoint: "Overall Survival",
    secondaryEndpoints: ["PFS", "ORR", "Duration of Response"],
    enrollment: 649,
    startDate: "March 2021",
    completionDate: "November 2025"
  },
  {
    id: "NCT05514054",
    title: "Dato-DXd in HR+/HER2-Low or HER2-Ultralow Breast Cancer (TROPION-Breast02)",
    sponsor: "AstraZeneca",
    phase: "Phase III",
    status: "Recruiting",
    indication: "HR+/HER2-Low Breast Cancer",
    primaryEndpoint: "Progression-Free Survival",
    secondaryEndpoints: ["Overall Survival", "ORR", "Clinical Benefit Rate", "Safety"],
    enrollment: 700,
    startDate: "August 2022",
    completionDate: "April 2027"
  }
];

export const defaultTrendingKeywords = [
  { keyword: "mRNA Therapeutics", count: 234, change: "+23%" },
  { keyword: "CAR-T Cells", count: 189, change: "+18%" },
  { keyword: "CRISPR", count: 167, change: "+12%" },
  { keyword: "AI Drug Discovery", count: 145, change: "+31%" },
  { keyword: "Antibody-Drug Conjugates", count: 98, change: "+8%" },
];

export const defaultAiInsights = [
  "Research output in mRNA therapeutics increased 23% month-over-month, primarily driven by COVID-19 vaccine platform extensions to oncology applications.",
  "CAR-T publications show growing focus on allogeneic approaches, with 34% of new papers addressing off-the-shelf manufacturing.",
  "Cross-referencing with clinical trial data suggests a 6-month lag between publication peaks and trial initiations in gene therapy space.",
];

export const defaultRegulatoryUpdates = [
  { id: "1", title: "FDA Updates CAR-T Manufacturing Guidelines", agency: "FDA", date: "Dec 15, 2024", priority: "high" as const, summary: "New quality control requirements for viral vector production in CAR-T cell therapies" },
  { id: "2", title: "EMA Revises Clinical Trial Application Process", agency: "EMA", date: "Dec 12, 2024", priority: "medium" as const, summary: "Streamlined submission pathway for first-in-human studies with enhanced safety monitoring" },
  { id: "3", title: "ICH E6(R3) GCP Guidelines Published", agency: "ICH", date: "Dec 10, 2024", priority: "high" as const, summary: "Major revision to Good Clinical Practice guidelines with focus on risk-based monitoring" },
  { id: "4", title: "PMDA Announces New Accelerated Approval Criteria", agency: "PMDA", date: "Dec 8, 2024", priority: "medium" as const, summary: "Japan expands conditional approval pathway for breakthrough therapies" },
  { id: "5", title: "FDA Issues Draft Guidance on AI in Drug Development", agency: "FDA", date: "Dec 5, 2024", priority: "high" as const, summary: "Framework for use of artificial intelligence and machine learning in drug discovery and clinical trials" },
  { id: "6", title: "EMA Updates Biosimilar Approval Requirements", agency: "EMA", date: "Dec 3, 2024", priority: "medium" as const, summary: "Revised guidance on analytical similarity and clinical trial requirements for biosimilars" },
  { id: "7", title: "Health Canada Introduces Agile Regulatory Pathway", agency: "HC", date: "Nov 28, 2024", priority: "medium" as const, summary: "New flexible framework for advanced therapy medicinal products including gene therapies" },
  { id: "8", title: "FDA Final Rule on Electronic Records and Signatures", agency: "FDA", date: "Nov 25, 2024", priority: "high" as const, summary: "Updated 21 CFR Part 11 requirements for electronic systems in pharmaceutical manufacturing" },
  { id: "9", title: "WHO Publishes mRNA Vaccine Guidelines", agency: "WHO", date: "Nov 22, 2024", priority: "high" as const, summary: "Global standards for quality, safety, and efficacy of mRNA-based vaccines and therapeutics" },
  { id: "10", title: "EMA Guidance on Real-World Evidence", agency: "EMA", date: "Nov 20, 2024", priority: "medium" as const, summary: "Framework for incorporating RWE in regulatory decision-making and label extensions" },
  { id: "11", title: "FDA Updates Orphan Drug Designation Criteria", agency: "FDA", date: "Nov 18, 2024", priority: "medium" as const, summary: "Clarifications on prevalence calculations and scientific rationale requirements" },
  { id: "12", title: "ICH Q12 Implementation Guidelines", agency: "ICH", date: "Nov 15, 2024", priority: "high" as const, summary: "Technical and regulatory considerations for pharmaceutical product lifecycle management" },
  { id: "13", title: "MHRA Post-Brexit Regulatory Updates", agency: "MHRA", date: "Nov 12, 2024", priority: "medium" as const, summary: "UK regulatory independence framework and mutual recognition agreements" },
  { id: "14", title: "FDA REMS Modification Guidance", agency: "FDA", date: "Nov 10, 2024", priority: "medium" as const, summary: "Updated requirements for Risk Evaluation and Mitigation Strategies modifications" },
  { id: "15", title: "EMA Pediatric Investigation Plans Update", agency: "EMA", date: "Nov 8, 2024", priority: "high" as const, summary: "Revised timelines and requirements for pediatric development programs" },
];

export const defaultInsightsData = {
  researchInsights: [
    { title: "mRNA Platform Expansion", summary: "mRNA therapeutics research has increased 23% with focus on oncology and rare disease applications beyond vaccines", impact: "high" as const, category: "research" },
    { title: "AI Drug Discovery Acceleration", summary: "Machine learning-driven target identification reducing early discovery timelines by 40%", impact: "high" as const, category: "research" },
    { title: "Gene Editing Clinical Translation", summary: "CRISPR and base editing therapies entering late-stage clinical development for hemoglobinopathies", impact: "medium" as const, category: "research" },
    { title: "Protein Degradation Momentum", summary: "PROTAC and molecular glue research expanding beyond oncology to neurodegeneration", impact: "medium" as const, category: "research" },
  ],
  trialsInsights: [
    { title: "Bispecific Antibody Wave", summary: "15+ bispecific antibody programs in registrational trials for hematologic malignancies", impact: "high" as const, category: "trials" },
    { title: "Cell Therapy Manufacturing Scale", summary: "Automated manufacturing reducing CAR-T production time from 3 weeks to 7 days", impact: "high" as const, category: "trials" },
    { title: "Decentralized Trial Adoption", summary: "40% of new oncology trials incorporating hybrid or fully decentralized elements", impact: "medium" as const, category: "trials" },
    { title: "Biomarker-Driven Enrollment", summary: "Precision medicine trials showing 2x higher success rates with companion diagnostics", impact: "high" as const, category: "trials" },
  ],
  regulatoryInsights: [
    { title: "Accelerated Approval Trends", summary: "FDA granted 73% more accelerated approvals in oncology year-over-year", impact: "high" as const, category: "regulatory" },
    { title: "Real-World Evidence Integration", summary: "EMA and FDA expanding RWE acceptance for label extensions and post-market studies", impact: "medium" as const, category: "regulatory" },
    { title: "Cell Therapy Guidelines Update", summary: "New FDA guidance on allogeneic cell therapy manufacturing and potency assays expected Q1 2025", impact: "high" as const, category: "regulatory" },
    { title: "AI/ML Regulatory Framework", summary: "ICH guidelines for AI in drug development under active discussion", impact: "medium" as const, category: "regulatory" },
  ],
  crossDomainRecommendations: [
    { title: "Prioritize mRNA-LNP Platform Development", description: "Strong research momentum combined with regulatory familiarity creates favorable development environment for mRNA therapeutics beyond vaccines", priority: "urgent" as const, domains: ["research", "regulatory"] },
    { title: "Invest in Decentralized Trial Capabilities", description: "Regulatory acceptance and patient preference driving shift toward hybrid trial models requiring digital infrastructure", priority: "high" as const, domains: ["trials", "regulatory"] },
    { title: "Develop Companion Diagnostics Early", description: "Biomarker-driven development showing significantly higher approval rates and faster timelines", priority: "high" as const, domains: ["research", "trials"] },
    { title: "Monitor Cell Therapy Manufacturing Innovation", description: "Automated manufacturing advances may shift competitive landscape in CAR-T and NK cell therapy", priority: "medium" as const, domains: ["research", "trials", "regulatory"] },
  ],
  marketTrends: {
    topTherapeuticAreas: ["Oncology", "Immunology", "Neurology", "Rare Diseases", "Metabolic Disorders"],
    emergingTechnologies: ["mRNA Therapeutics", "Gene Editing", "Protein Degraders", "Digital Therapeutics", "AI Drug Discovery"],
    keyPlayers: ["Moderna", "BioNTech", "CRISPR Therapeutics", "Intellia", "Arvinas", "Bristol Myers Squibb", "Roche", "Pfizer"],
  },
  executiveSummary: "The pharmaceutical landscape shows strong momentum in nucleic acid therapeutics, cell and gene therapy, and AI-enabled drug discovery. Regulatory agencies are increasingly supportive of novel modalities with multiple accelerated pathways available. Key opportunities exist at the intersection of precision medicine and decentralized trial models.",
};
